Drug Discovery
Onco-Innovations Advances PNKP Inhibitor ONC010 as Emerging DDR Therapy
Onco-Innovations Ltd. is developing ONC010, a nanoparticle-encapsulated PNKP inhibitor targeting DNA repair pathways, positioning itself in the DDR therapy market with AI-driven precision oncology capabilities.
Quantum BioPharma Completes Phase 1 Trial for Multiple Sclerosis Therapy Lucid-MS
Quantum BioPharma announces completion of Phase 1 clinical studies for Lucid-MS, a therapy targeting myelin repair in multiple sclerosis, and submission of an IND application to the FDA.
Redwood AI's AI-Powered Chemistry Platform Targets Drug Discovery and Defense Markets
Redwood AI is developing a proprietary AI platform for drug discovery and chemical analysis, positioning itself across pharmaceutical, defense, and public safety markets through research collaborations and government-supported initiatives.
Quantum BioPharma Advances Multiple Sclerosis Therapy with LUCID-MS Program, Completes Phase 1 Trials
Quantum BioPharma has completed Phase 1 clinical studies for LUCID-MS, a therapy targeting myelin repair in multiple sclerosis, and filed an IND with the FDA, addressing the critical unmet need for neuroprotective treatments.
Oncotelic Therapeutics to Showcase AI Drug Discovery Platform at Qdrant Vector Space Day 2026
Oncotelic Therapeutics will present its proprietary PDAOAI platform at Qdrant Vector Space Day 2026, highlighting how it accelerated two drug candidates from concept to investigational new drug filings in under two years, significantly reducing time and cost.
Lifordi Immunotherapeutics Reports Positive Phase 1 Data for LFD-200 in Autoimmune Disease
Phase 1 data for LFD-200, a subcutaneous glucocorticoid antibody-drug conjugate, shows anti-inflammatory activity without systemic steroid toxicity, with patient dosing ongoing in rheumatoid arthritis.
HighTide Therapeutics Unveils New Data Supporting HTD1801's Renoprotective Effects at ERA 2026
New findings from HighTide Therapeutics show that its lead candidate HTD1801 protects kidney function by targeting podocyte inflammation and apoptosis, offering potential as a disease-modifying therapy for chronic kidney disease.
TransCode Therapeutics Reports Positive Phase 1a Results for TTX-MC138, Paving Way for Phase 2a Trial
TransCode Therapeutics announced positive Phase 1a results for its investigational microRNA-10b inhibitor TTX-MC138, showing durable disease stabilization and no dose-limiting toxicities, supporting advancement to Phase 2a clinical development.
Quantum BioPharma Advances Multiple Sclerosis Drug Candidate Lucid-MS and Commercial Product unbuzzd™
Quantum BioPharma's lead drug Lucid-MS targets nerve damage in multiple sclerosis, with a Phase 2 trial upcoming, while its alcohol metabolism product unbuzzd™ generates royalty revenue.
iOrganBio Adds Leading Neurobiologist Dr. Zhiping Pang to Scientific Advisory Board
iOrganBio appoints Dr. Zhiping Pang, a top expert in human neuron biology and neuropsychiatric disorders, to its Scientific Advisory Board, strengthening its position in AI-enabled human cell manufacturing for research and therapeutics.
Quantum BioPharma Advances Multiple Sclerosis Program with Differentiated Approach
Quantum BioPharma is progressing its clinical-stage multiple sclerosis program targeting demyelination, a novel strategy distinct from immune-modulating therapies, while maintaining a diversified portfolio including consumer wellness products and sufficient capital through 2028.
Sino Biological's Cell-Free Protein Synthesis Powers AI-Driven Protein Design Study Published in Nature Communications
Sino Biological's XPressMAX Cell-Free Protein Synthesis Kit enabled rapid experimental validation of AI-designed proteins in a study by Tencent AI for Life Sciences Lab, achieving over 100-fold activity improvements and thermostable enzymes.
Redwood AI and Resilience Biosciences Partner to Accelerate Drug Discovery with AI
Redwood AI Corp. has entered a collaboration with Resilience Biosciences to apply AI-driven computational chemistry for faster, more efficient small-molecule drug development, particularly targeting non-opioid therapeutics.
NanoViricides Proposes NV-387 for Bundibugyo Ebola Outbreak Amid Lack of Approved Treatments
NanoViricides highlights its broad-spectrum antiviral NV-387 as a potential treatment for the Bundibugyo Ebola outbreak in Africa, where no approved vaccines or therapies exist, leveraging its host-targeted mechanism and oral formulation for easier deployment.
Oncotelic Therapeutics Integrates 28 Million Scientific Abstracts into AI Platform, Signaling Shift in Drug Discovery
Oncotelic Therapeutics has integrated 28 million scientific abstracts into its PDAOAI platform, positioning itself as a key player in the rapidly growing AI drug-discovery market.
SureNano Science Targets Obesity Market with Novel GLP-1 Therapy GEP-44
SureNano Science Ltd. is advancing a differentiated GLP-1-based therapy, GEP-44, aiming to compete in the rapidly growing obesity and metabolic disease market dominated by blockbusters like Ozempic and Wegovy.
Graphene Quantum Dots Show Promise in Targeting Parkinson's-Related Protein Clumping
A new study reveals that graphene quantum dots can interfere with the aggregation of misfolded proteins linked to Parkinson's disease, offering a potential new direction for therapeutic exploration.
Telomir Pharmaceuticals Reports Preclinical Data Showing Telomir-Zn Benefits in Wilson’s Disease Model
Telomir Pharmaceuticals announced peer-reviewed preclinical data demonstrating that Telomir-Zn improved survival and reduced oxidative stress and copper burden in a Wilson’s disease model, expanding the drug’s potential beyond its lead cancer program.
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Driven Antibody Discovery
Sino Biological's new XPressMAX™ Cell-Free Protein Synthesis Kit enables ultra-fast protein synthesis in three hours, supporting AI-powered high-throughput antibody drug discovery by eliminating traditional cell-based constraints.
SureNano Science's GEP-44 Could Disrupt the Obesity Drug Market with Improved Tolerability
SureNano Science Ltd. is advancing GEP-44, a next-generation GLP-1 therapy with a triple agonist mechanism, aiming to improve upon current obesity treatments by offering better tolerability and potential non-injectable delivery.
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
The rising prevalence of obesity and type 2 diabetes is driving significant interest in next-generation GLP-1 therapies, with companies like SureNano Science Ltd. developing novel triple agonists that could improve efficacy and tolerability in a rapidly expanding market.
Kairos Pharma CEO to Present at LD Micro Invitational, Highlighting Clinical Progress
Kairos Pharma CEO Dr. John Yu will present at the LD Micro Invitational, providing updates on the company's clinical trials for ENV-105, a promising oncology candidate targeting drug resistance in cancer.
NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship
NanoViricides points to its clinical-stage antiviral candidate NV-387 as a potential broad-spectrum therapeutic following an Andes hantavirus incident aboard a cruise ship, underscoring the need for versatile antiviral treatments.
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provisional patent application.
Blocking Fructose Metabolism Shows Promise Against Pediatric Brain Cancer
New research from Johns Hopkins reveals that disrupting fructose metabolism in tumor cells could slow group 3 medulloblastoma, a deadly childhood brain cancer, offering a potential new treatment avenue.
Lantern Pharma Expands predictBBB Platform into Large Quantitative Model for Drug Discovery
Lantern Pharma announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), enabling real-time molecular intelligence for drug discovery, which could accelerate development and reduce costs.
Oncotelic's PDAOAI Platform Targets AI Bias in Pharma with Evidence-Interrogation Approach
Oncotelic Therapeutics' PDAOAI platform indexes over 125,000 PubMed abstracts on TGF-β signaling to generate testable hypotheses, addressing transparency and bias challenges in AI-driven drug discovery.
LIXTE Biotechnology Advances Precision Oncology with Novel PP2A Inhibitor LB-100
LIXTE Biotechnology Holdings is developing LB-100, a first-in-class PP2A inhibitor that enhances chemotherapy and immunotherapy while reducing side effects, with ongoing clinical trials for ovarian and colon cancers.
Lantern Pharma to Showcase AI Co-Scientist Platform withZeta.ai in Live Public Demo
Lantern Pharma will host its first live demonstration of the withZeta.ai AI co-scientist platform on April 30, 2026, showcasing its ability to accelerate oncology drug discovery and marking a potential new revenue stream through a subscription model.
SureNano Science Advances GLP-1 Drug Candidate Toward Clinical Trials, Expands Investor Outreach
SureNano Science Ltd. is moving its lead obesity and diabetes drug GEP-44 into FDA IND-enabling studies with LabCorp while broadening investor communications through a partnership with Investor Brand Network.